Otro
Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review
Registro en:
Biomed Research International. New York: Hindawi Publishing Corporation, v. 2015, p. 1-22, 2015.
2314-6133
WOS:000355087900001
WOS000355087900001.pdf
Autor
Rigon, Roberta Balansin
Oyafuso, Marcia Helena
Fujimura, Andressa Terumi
Goncalez, Maria Lima
Prado, Alice Haddad do
Gremião, Maria Palmira Daflon
Chorilli, Marlus
Resumen
Melanoma (MEL) is a less common type of skin cancer, but it is more aggressive with a high mortality rate. The World Cancer Research Fund International (GLOBOCAN 2012) estimates that there were 230,000 new cases of MEL in the world in 2012. Conventional MEL treatment includes surgery and chemotherapy, but many of the chemotherapeutic agents used present undesirable properties. Drug delivery systems are an alternative strategy by which to carry antineoplastic agents. Encapsulated drugs are advantageous due to such properties as high stability, better bioavailability, controlled drug release, a long blood circulation time, selective organ or tissue distribution, a lower total required dose, and minimal toxic side effects. This review of scientific research supports applying a nanotechnology-based drug delivery system for MEL therapy. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)